影响肝细胞癌中 TIL（肿瘤浸润淋巴细胞）浸润的关键致癌信号通路：基本原理与最新进展

英文原题：Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.

查看英文原题

Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.

PubMed 2024/02/15（内容时间） Front Immunol Q1 · IF 7（JCR 2025）

技术：TIL 肝细胞癌地区：中国

登录后收藏与关注全文解读加入对比

研究概要

肝细胞癌（HCC）的发病率在原发性肝癌中居首位，其死亡率呈逐年持续上升趋势。

中文摘要

肝细胞癌（HCC）的发病率在原发性肝癌中居首位，其死亡率呈逐年持续上升趋势。近年来，HCC的治疗取得了显著进展，靶向免疫治疗作为早期手术切除的辅助手段崭露头角。使用TIL（肿瘤浸润淋巴细胞）的过继细胞疗法（ACT）在其他类型的实体瘤中已显示出令人鼓舞的结果。本文旨在全面概述不同类型TIL之间的复杂相互作用及其对HCC的影响，阐明通过TIL靶向新抗原的策略，并探讨TIL治疗中遇到的挑战及潜在解决方案。此外，本文特别审视了HCC肿瘤微环境中致癌信号通路激活对TIL浸润动态的影响。同时，简要概述了TIL制备技术以及针对实体瘤中基于TIL的免疫治疗的临床试验最新进展。

展开英文摘要原文

The incidence of hepatocellular carcinoma (HCC) ranks first among primary liver cancers, and its mortality rate exhibits a consistent annual increase. The treatment of HCC has witnessed a significant surge in recent years, with the emergence of targeted immune therapy as an adjunct to early surgical resection. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has shown promising results in other types of solid tumors. This article aims to provide a comprehensive overview of the intricate interactions between different types of TILs and their impact on HCC, elucidate strategies for targeting neoantigens through TILs, and address the challenges encountered in TIL therapies along with potential solutions. Furthermore, this article specifically examines the impact of oncogenic signaling pathways activation within the HCC tumor microenvironment on the infiltration dynamics of TILs. Additionally, a concise overview is provided regarding TIL preparation techniques and an update on clinical trials investigating TIL-based immunotherapy in solid tumors.

论文信息

作者: Wang X、Yuan Z、Li Z、He X、Zhang Y、Wang X、Su J、Wu X
单位: Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China.China
文献类型: 综述 · 非美国政府资助研究
期刊: Frontiers in immunology2024

原文标识: PubMed 38426090　·　DOI 10.3389/fimmu.2024.1354313

在 PubMed 查看 → 出版商原文（DOI）报告译文或资料问题 →